A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-29 and is reviewed periodically as new material appears.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
The growth solution requires a low concentration of a metal precursor, ligands that will readily exchange with preexisting seed ligands, and a weak or very low concentration of reducing agent. The reducing agent must not be strong enough to reduce metal precursor in the growth solution in the absence of seeds. Otherwise, the growth solution will form new nucleation sites instead of growing on preexisting ones (seeds). Growth is the result of the competition between surface energy (which increases unfavorably with growth) and bulk energy (which decreases favorably with growth). The balance between the energetics of growth and dissolution is the reason for uniform growth only on preexisting seeds (and no new nucleation). Growth occurs by the addition of metal atoms from the growth solution to the seeds, and ligand exchange between the growth ligands (which have a higher bonding affinity) and the seed ligands. Range and direction of growth can be controlled by nanoseed, concentration of metal precursor, ligand, and reaction conditions (heat, pressure, etc.). Controlling stoichiometric conditions of growth solution controls ultimate size of particle. For example, a low concentration of metal seeds to metal precursor in the growth solution will produce larger particles. Capping agent has been shown to control direction of growth and thereby shape. Ligands can have varying affinities for binding across a particle. Differential binding within a particle can result in dissimilar growth across particle.
Unlike in New Spain and Central America, in South America independence was spurred by the pro-independence fighters who had held out for the past half-decade. José de San Martín and Simón Bolívar inadvertently led a continent-wide pincer movement from southern and northern South America that liberated most of the Spanish American nations on that continent. After securing the independence of Chile in 1818, San Martín concentrated on building a naval fleet in the Pacific to counter Spanish control of those waters and reach the royalist stronghold of Lima. By mid-1820 San Martín had assembled a fleet of eight warships and sixteen transport ships under the command of Admiral Cochrane. The fleet set sail from Valparaíso to Paracas in southern Peru. On 7 September, the army landed at Paracas and successfully took Pisco. After this, San Martín, waiting for a generalized Peruvian revolt, chose to avoid direct military confrontation. San Martín hoped that his presence would initiate an authentic Peruvian revolt against Spanish rule, believing that otherwise any liberation would be ephemeral. In the meantime, San Martín engaged in diplomacy with Viceroy Joaquín de la Pezuela, who was under orders from the constitutional government to negotiate on the basis of the 1812 Constitution and to maintain the unity of the Spanish monarchy. However, these efforts proved fruitless, since independence and unity of the monarchy could not be reconciled, so the army sailed in late October to a better strategic position in Huacho, in northern Peru.
Glutathione, along with oxidized glutathione (GSSG) and S-nitrosoglutathione (GSNO), have been found to bind to the glutamate recognition site of the NMDA and AMPA receptors (via their γ-glutamyl moieties), and may be endogenous neuromodulators. At millimolar concentrations, they may also modulate the redox state of the NMDA receptor complex. In addition, glutathione has been found to bind to and activate ionotropic receptors that are different from any other excitatory amino acid receptor, and which may constitute glutathione receptors, potentially making it a neurotransmitter. As such, since N-acetylcysteine is a prodrug of glutathione, it may modulate all of the aforementioned receptors as well. Glutathione also modulates the NMDA receptor by acting at the redox site. Acetylcysteine also is a precursor to cystine, which in turn is a substrate for the cystine-glutamate antiporter on astrocytes; hence there is increasing glutamate release into the extracellular space. This glutamate in turn acts on mGluR2/3 receptors, and at higher doses of acetylcysteine, mGluR5. Acetylcysteine may have other biological functions in the brain, such as the modulation of dopamine release and the reduction in inflammatory cytokine formation possibly via inhibiting NF-κB and modulating cytokine synthesis.
Sources: en.wikipedia.org
Cyproheptadine is used to treat allergic reactions (specifically hay fever). There is evidence supporting its use for allergies, but second generation antihistamines such as ketotifen and loratadine have shown equal results with fewer side effects. It is also used as a preventive treatment against migraine. In a 2013 study the frequency of migraine was dramatically reduced in patients within 7 to 10 days after starting treatment. The average frequency of migraine attacks in these patients before administration was 8.7 times per month, this was decreased to 3.1 times per month at 3 months after the start of treatment. This use is on the label in the UK and some other countries. It is also used off-label in the treatment of cyclical vomiting syndrome in infants; the only evidence for this use comes from retrospective studies. Cyproheptadine is sometimes used off-label to improve akathisia in people on antipsychotic medications. It is used off-label to treat various dermatological conditions, including psychogenic itch, drug-induced hyperhidrosis (excessive sweating), and prevention of blister formation for some people with epidermolysis bullosa simplex. One of the effects of the drug is increased appetite and weight gain, which has led to its use (off-label in the USA) for this purpose in children who are wasting as well as people with cystic fibrosis.
== Reception == Ben Rogers reviewed the Fat Duck for The Independent in 1996, before it had gained any Michelin stars. He discovered that Blumenthal was cooking foie gras in sherry to give it a nutty flavour, but Rogers was not sure if this was warranted. He praised a jambonneau of duck, but found the monkfish rubbery. He described the menu as "awkwardly written, badly punctuated, and at points quite impenetrable". After the Fat Duck received its first Michelin star, David Fingleton visited it for The Spectator in 1999, and found the experience "beyond reproach; unsullied pleasure from start to finish". In 2001, Terry Durack reviewed the Fat Duck for The Independent. He was initially hesitant, expecting tricks straight away, but was surprised to find a bowl of normal green olives on the table as he arrived. He did not enjoy a mustard ice cream in a red cabbage gazpacho soup, but described the restaurant as "great" and gave it a score of 17 out of 20. In 2004, following the third Michelin star, Jan Moir of The Daily Telegraph gave it a negative review, saying that "while many of the flavours are politely interesting, the relentless pappy textures of mousses and foams and creams and poached meats really begins to grate". She also found it overpriced, calling it the "Fat Profit". Matthew Fort reviewed the Fat Duck for The Guardian in 2005, and wrote that "there is no doubt that the Fat Duck is a great restaurant and Heston Blumenthal the most original and remarkable chef this country has ever produced". In The Times, A. A.
=== Droplet incubation === In order to make droplet-based microfluidics a viable technique for carrying out chemical reactions or working with living cells on the microscale, it is necessary to implement methods allowing for droplet incubation. Chemical reactions often need time to occur, and living cells similarly require time to grow, multiply, and carry out metabolic processes. Droplet incubation can be accomplished either within the device itself (on-chip) or externally (off-chip), depending on the parameters of the system. Off-chip incubation is useful for incubation times of a day or more or for incubation of millions of droplets at a time. On-chip incubation allows for integration of droplet manipulation and detection steps in a single device.
Sources: en.wikipedia.org
== Early life == Born William Beckett on 10 September 1826, he was the third and second surviving son of Sir Edmund Beckett, 4th Baronet, of Grimthorpe, Yorkshire, and his wife Maria Beverley, daughter of William Beverley of Beverley. He was educated at Rugby School and Trinity College, Cambridge.
== Applications == Variable pathlength techniques can be applied in any situation where Beer's law can be applied. It provides an analytical method that averages out minor variations in sample preparation consistency. It also provides a means to calculate concentrations without calibrations curves or serial dilution of samples. Variable pathlength absorption spectroscopy is typically used when highly reproducible data is a necessity. This can be in the fields of medicine, biotechnology, pharmacology, and drug discovery. It is particularly useful in the protein purification stage of biotechnology where accurate concentrations of various proteins are required or in crystallography. Determining the relative ratio of protein to DNA is common practice and can be calculated by finding the slope at the corresponding absorption peaks and taking their ratio. This method is used to find the purity of a sample containing these two types of molecule.
=== ECG findings === With mild to moderate hyperkalemia, there may be prolongation of the PR interval and development of peaked T waves. The measurement properties (sensitivity and specificity) of ECG to predict laboratory hyperkalemia, or to predict more severe arrhythmia in the context of hyperkalemia, are not known. Severe hyperkalemia results in a widening of the QRS complex, and the ECG complex can evolve to a sinusoidal shape. There appears to be a direct effect of elevated potassium on some of the potassium channels that increases their activity and speeds membrane repolarisation. Also, (as noted above), hyperkalemia causes an overall membrane depolarization that inactivates many sodium channels. The faster repolarisation of the cardiac action potential causes the tenting of the T waves, and the inactivation of sodium channels causes a sluggish conduction of the electrical wave around the heart, which leads to smaller P waves and widening of the QRS complex. Some of the potassium currents are sensitive to extracellular potassium levels, for reasons that are not well understood. As the extracellular potassium levels increase, potassium conductance is increased so that more potassium leaves the myocyte in any given period. To summarize, classic ECG changes associated with hyperkalemia are seen in the following progression: peaked T wave, shortened QT interval, lengthened PR interval, increased QRS duration, and eventually absence of the P wave with the QRS complex becoming a sine wave.
There are six autonomous public universities in Singapore, including National University of Singapore founded in 1905, Nanyang Technological University founded 1981, Singapore Management University founded in 2000, Singapore University of Technology and Design and Singapore Institute of Technology founded in 2009, and Singapore University of Social Sciences founded in 2017.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.